DailyIQ
Last updatedjust now

CL·Colgate-Palmolive Company

$87.25
+1.06 (+1.23%)
After Hours
High
$88.05
Open
$86.55
Market Cap
67.82B
52W High
$99.33
Low
$86.15
P. Close
$87.25
P/E
33.29
52W Low
$74.26
Fwd P/E
21.03
DailyIQ Est.
$99.85
Inst. Ownership
37.2%
Short Interest
2.37%
Days to Cover
4.0
Technical Score (1D)
23
BEARISH
News Sentiment
50
MIXED
On Oct 6, a comparison of Colgate‑Palmolive (CL) and Clorox (CLX) highlighted that CL’s global scale and category leadership across oral, personal, and home care give it a defensive edge. The article noted that CL’s diversified product portfolio and strong emerging‑market presence support its long‑term appeal. CLX, by contrast, is focused on regaining market share and expanding its health and hygiene platform through the GOJO acquisition. Both companies are reported to use pricing strategies, revenue growth management, and digital capabilities to navigate inflationary pressures and shifting consumer habits. The comparison underscored how brand strength, portfolio positioning, and growth strategies shape each firm’s defensive profile.
LOW TARGET
$87 -0.3%
2 analysts
MEAN TARGET
$99 +13.0%
18 analysts
HIGH TARGET
$110 +26.1%
12 analysts
PRICE RANGE
$87.00 - $110.00
SB / B / H / S / SS
5/15/10/1/1
DAILYIQ EST.
$99.85 (+14.4%)
Sector
Consumer Defensive
Industry
Household & Personal Products
Exchange
NYQ
Country
United States
Symbol
CL
Description
Colgate-Palmolive is a global consumer goods company focused on two primary segments: Oral, Personal and Home Care, and Pet Nutrition. The company's core business revolves around the manufacturing and distribution of a wide array of well-known brands, including Colgate, Palmolive, and Hill's Science Diet. Its Oral, Personal and Home Care segment offers a diverse portfolio of essential products, from toothpaste and soap to household cleaners, sold through various retail channels, including online platforms. Complementing this, the Pet Nutrition division provides nutritional products for pets, catering to both everyday needs and therapeutic requirements, distributed through pet supply retailers and veterinary professionals. Founded in 1806, Colgate-Palmolive maintains a strong presence in the consumer market, offering established brands and a broad distribution network.
Bought (1Y)
0 shares
$0
Sold (1Y)
385,826 shares
$35.4M
BILBREY JOHN P-
Award/Grant271 shares2026-10-01
Newman Brian-
Award/Grant214 shares2026-10-01
NORRINGTON LORRIE M-
Award/Grant300 shares2026-10-01
Malcolm GregoryEVP and Controller
Award/Grant7,477 shares2026-09-16
Malcolm GregoryEVP and Controller
Award/Grant1,081 shares2026-09-16
63/ 100
Neutral / mixed
Overall: Neutral
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
60.1%
Net Margin
10.5%
Revenue CAGR
2.2%
Current Ratio
0.83x
Debt / Equity
147.89x
Return on Equity
3948.1%
Earnings Summary
Colgate‑Palmolive is a global consumer goods company that operates primarily in the Oral, Personal and Home Care and Pet Nutrition segments, offering well‑known brands such as Colgate, Palmolive and Hill’s Science Diet through a broad retail and veterinary distribution network. The firm is a staple of the Consumer Defensive sector, delivering essential household and personal products that tend to be resilient in varying economic climates. In the most recent quarters, Colgate‑Palmolive posted EPS of $0.91 in Q4 2024 and Q1 2025, both beating the $0.889 and $0.858 estimates, and maintained a steady revenue of $4.94 billion and $4.91 billion respectively. The company’s EPS continued to rise to $0.92 in Q2 2025 and $0.91 in Q3 2025, while revenue climbed to $5.11 billion and $5.13 billion, indicating a modest acceleration in top‑line growth and a consistent beat of analyst expectations in four of the last five quarters. Historically, Colgate‑Palmolive has shown a steady YoY revenue growth trajectory, with EPS generally outperforming estimates even when revenue growth decelerated, as seen in Q4 2025 where EPS of $0.95 surpassed the $0.94 estimate despite revenue falling slightly to $5.23 billion from $5.27 billion. This pattern of robust earnings relative to revenue trends underscores the company’s efficient cost management and pricing power. Recent news highlights a strategic portfolio realignment, with the sale of mass‑market personal‑care brands expected to generate over $1 billion in cash, and a continued dividend‑king trajectory that saw a 63rd consecutive dividend increase and a $3.9 billion free‑cash‑flow supporting a 43% payout ratio.

EPS

EstBeatMiss
$0.87$0.91$0.94$0.97$1.01Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$0.93 - -
Q2'26$0.98$0.99+1.5%
Q1'26$0.96$0.97+1.4%
Q4'25$0.94$0.95+1.1%
Q3'25$0.89$0.91+2.4%
Q2'25$0.89$0.92+2.8%

Revenue

EstBeatMiss
$5.0B$5.2B$5.3B$5.4B$5.6BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$5.5B - -
Q2'26$5.5B$5.4B-2.9%
Q1'26$5.3B$5.3B-0.2%
Q4'25$5.3B$5.2B-0.8%
Q3'25 - $5.1B -
Q2'25 - $5.1B -

Market Data

CL Stock Snapshot

BEARISH23/100
$87.25+$0.00 (0.0%)
Market cap
67.82B
P/E ratio
33.3
Day range
$86.15 – $88.05
News sentiment
50/100 · Neutral
Analyst target
$98.60 (+13.0%)
Consensus
Buy · 32 analysts
52-week range+17.5% off low · -12.2% from high
$74.26$99.33
Price $87.25 DailyIQ Est. $99.85

CL is on the weaker side of its setup, with little confirmation for a reversal yet. Earnings and guidance carry more weight than macro data at this capitalisation.

Reverse DCF

What growth is priced into CL?

CHEAP

At today's price, Colgate-Palmolive Company needs to grow free cash flow about -2.1% a year for the next 10 years to justify its valuation at a 6.53% cost of capital. Over its actual history it has compounded free cash flow at 2.5% a year, so the market is asking for 4.6 percentage points below its own delivered rate. On that basis CL looks priced below what its own growth record supports.

Implied FCF growth
-2.1%
Historical FCF CAGR
2.5%
Growth gap
-4.6 pts
Verdict
CHEAP
Discount rate (WACC)
6.53%
Beta
0.35

Behaviour On Record

What CL's own history says about today's numbers

Realized volatility (21d)
13.5% 29th pct
Below its peak
-20.8%
vs 200-day average
-2.6%
Up days (1y)
51%

Colgate-Palmolive Company is currently running 13.5% annualised volatility over the last 21 sessions. Measured against CL's own 13 years of daily returns rather than a market-wide average, that is the 29th percentile — on the quiet side for this stock, against a typical reading of 15.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

CL is trading -20.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -15.8%, and the deepest was -25.3% in 2018. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -2.6% from its 200-day moving average. Against every other day in its history, that gap ranks at the 30th percentile — a narrower gap than it typically runs. Over the past year CL closed higher on 51% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 13 years of records, CL finished the month higher 7 of 13 times, with a median return of +0.6% and an average of -0.2%. Its strongest month historically has been November at +2.4% on average, its weakest September at -2.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: CL has opened more than 2% away from the prior close in 27 of 3,267 sessions (0.8% of the time), with the largest gaps running +4.7% and -6.4%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, CL moved an average of 1.9% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.8% and a largest of +2.9%.

All figures computed from 3,268 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against CL's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of CL's sector?

Colgate-Palmolive Company sits in the Consumer Staples sector, currently ranked 7th of 12 GICS sectors by relative-strength rotation score (lagging).

Sector rank
#7 of 12
Sector state
Lagging
Sector rotation score
27

Options Market

What is the options market pricing for CL?

CallsPuts

For Colgate-Palmolive Company's nearest expiry (2026-10-09, 3 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.33), with at-the-money implied volatility around 40.5%. The options market is pricing roughly a ±2.9% move by that expiry — a range of about $82.25–$87.13.

Put/call ratio (2026-10-09)
0.33
ATM implied volatility
40.5%
Total open interest
875
Expected move by 2026-10-09
±2.9% ($82.25–$87.13)

Analyst Rating Changes

Are analysts turning bullish or bearish on CL?

Piper Sandler most recently reiterated its rating on Colgate-Palmolive Company to Overweight on Sep 21, 2026 with a price target of $95 (from $98). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Piper Sandler — Overweight
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Sep 21, 2026Piper SandlerMaintainedOverweight$98 → $95
Sep 8, 2026RBC CapitalReiteratedOutperform$104
Aug 3, 2026UBSMaintainedBuy$106 → $109
Aug 3, 2026TD CowenMaintainedHold$85 → $90
Aug 3, 2026JP MorganMaintainedOverweight$104 → $103
Aug 3, 2026RBC CapitalMaintainedOutperform$102 → $104
Aug 3, 2026Evercore ISI GroupMaintainedOutperform$100 → $101
Jul 21, 2026BarclaysMaintainedEqual-Weight$80 → $87
Jul 16, 2026JP MorganMaintainedOverweight$96 → $104
Jul 16, 2026UBSMaintainedBuy$100 → $106
Jul 14, 2026CitigroupMaintainedBuy$105 → $110
Jul 9, 2026Piper SandlerMaintainedOverweight$92 → $96

CL Competitive Positioning

Colgate-Palmolive Company (CL) is tracked alongside these names in Household & Personal Products on DailyIQ — ranked by market cap, with today's move alongside.

News Sentiment Analysis

Sentiment gathered from recent headlines

50/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
The article contrasts Colgate-Palmolive (CL) with Clorox (CLX), highlighting CL’s global scale, category leadership, and diversified product portfolio across oral, personal, and home care. It notes CL’s strong emerging‑market presence and innovation pipeline, while CLX focuses on rebuilding market share, enhancing productivity, and expanding its health and hygiene platform through the GOJO acquisition. Both firms employ pricing, revenue growth management, and digital capabilities to navigate inflationary pressures and shifting consumer habits. The comparison underscores how brand strength, portfolio positioning, and growth strategies shape each company’s long‑term defensive appeal.
What did this article say?
Wells Fargo reduced its price target for Colgate-Palmolive (CL) from $95 to $90 while maintaining an equalweight rating. The downgrade reflects a reassessment of CL’s valuation relative to peers. The change signals a modest negative outlook for the company’s stock, though the rating remains unchanged. Investors may view the adjustment as a cautious recalibration rather than a drastic shift.
What did this article say?
Colgate‑Palmolive (CL) announced a strategy focused on innovation, premiumization, and expansion into emerging markets to strengthen its brand portfolio and support long‑term growth. The company highlighted new differentiated oral‑care products, including electric toothbrushes and specialized toothpastes, aimed at higher‑value categories. CL’s emphasis on consumer‑centric product development is intended to improve its product mix, boost revenue, and enhance margins. The approach signals a continued commitment to maintaining a competitive edge in the global consumer‑products market.
What did this article say?
Colgate‑Palmolive (CL) continued its long‑standing dividend‑king trajectory, having raised its dividend for 63 consecutive years. The company’s strong free‑cash‑flow generation of $3.9 billion supported a payout ratio of 43% and a current quarterly dividend of $0.53 per share. With over 40% of the global toothpaste market and a portfolio of personal and home‑care brands, CL’s business model delivers resilient margins and consistent cash flow. The dividend yield of approximately 2.4% to 3% positions CL as a stable income play amid economic uncertainty. Investors view the company’s dividend history as a low‑risk, long‑term income opportunity.
What did this article say?
Colgate‑Palmolive announced it was working with Goldman Sachs to sell several mass‑market personal care brands, including Softsoap, Irish Spring and Speed Stick. The divestiture is expected to generate more than $1 billion in cash, which the company plans to use to strengthen its balance sheet and fund future growth initiatives. The move aligns with a broader strategy to streamline the portfolio and focus on higher‑margin core categories. By unlocking capital, Colgate aims to improve its deleveraging profile and increase financial flexibility for strategic investments.
What did this article say?
The article compares Colgate‑Palmolive (CL) with National Vision (EYE) for value investors. It notes CL holds a Zacks Rank of #3 (Hold) while EYE has a #2 (Buy) rank, indicating a stronger earnings outlook improvement for EYE. Value metrics such as P/E and other traditional ratios are highlighted, with CL appearing less attractive. The piece suggests CL may be a less compelling value play at present. No material corporate action or earnings surprise is reported.
What did this article say?
BNP Paribas reduced its price target for Colgate‑Palmolive (CL) from $101 to $97 while keeping an outperform rating. The bank cited recent earnings and market conditions as reasons for the downward adjustment. The target cut signals a modest negative outlook for CL’s stock, though the overall recommendation remains bullish. Investors may view the change as a slight headwind but not a material shift in the company’s valuation.
What did this article say?
Colgate‑Palmolive’s share price recently dipped, prompting investors to reassess whether the current valuation aligns with the company’s cash‑flow generation. The stock closed at US$86.06, while the firm has delivered a 29.8% return over the past three years. Analysts noted that the established household‑products model supports steady cash generation, so minor shifts in future cash‑flow expectations or reinvestment needs could influence the share price. No new earnings guidance or material events were disclosed, leaving the valuation question largely speculative.

Technical Analysis

Real-time indicators across multiple timeframes

23
BEARISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $25.22B combined position · 9 adding, 15 trimming, 1 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy83,947,98710.80%$6.63B2026-01-29
BlackRock, Inc.▼ Sell69,915,4729.00%$6.41B2026-08-07
Geode Capital Management, LLC▲ Buy23,144,3192.98%$2.14B2026-08-12
Morgan Stanley▲ Buy22,072,9252.84%$2.02B2026-08-13
Norges Bank▼ Sell9,686,0291.25%$888.02M2026-08-12
FMR LLC (Fidelity)▼ Sell8,983,0711.16%$823.57M2026-08-13
Goldman Sachs Group Inc▼ Sell8,571,0151.10%$785.79M2026-08-14
Northern Trust Corp▼ Sell8,471,5751.09%$776.67M2026-08-13
Invesco Ltd.▼ Sell8,325,6121.07%$763.29M2026-08-14
Bank of America Corp▼ Sell6,189,8240.80%$567.48M2026-08-14
Citadel Advisors LLC• Hold5,406,6870.70%$495.69M2026-09-02
Wellington Management Group LLP▼ Sell5,111,3130.66%$468.61M2026-08-14
AQR Capital Management LLC▲ Buy4,665,2940.60%$426.78M2026-08-14
AllianceBernstein L.P.▲ Buy4,518,3670.58%$385.10M2026-08-14
Wells Fargo & Company▼ Sell3,934,3740.51%$360.70M2026-08-14
JPMorgan Chase & Co▼ Sell3,395,2810.44%$313.72M2026-08-12
Neuberger Berman Group LLC▼ Sell2,251,3980.29%$206.55M2026-08-13
Millennium Management LLC▲ Buy1,465,3460.19%$134.34M2026-08-14
Citigroup Inc▲ Buy1,408,4240.18%$129.12M2026-08-03
Susquehanna International Group, LLP▼ Sell1,244,4250.16%$114.09M2026-08-14
Man Group plc▲ Buy966,9920.12%$88.65M2026-08-14
Renaissance Technologies LLC▼ Sell881,9330.11%$80.86M2026-08-13
Balyasny Asset Management L.P.▲ Buy755,5670.10%$69.27M2026-08-14
Point72 Asset Management, L.P.▼ Sell742,2550.10%$68.05M2026-08-14
Prudential Financial Inc▼ Sell695,7630.09%$63.79M2026-08-12
Q2 2026 flow:6.32M sh bought ($573.77M)9.21M sh sold ($845.10M)net -2.90M sh (−$271.33M)
Congressional Trading Activity
18 disclosed trades · ~$144.0K est. traded value · 5 buys, 13 sells
MemberChamberStateTypeAmountTradedFiled
Kevin HernHouseOK01▼ Sell$1K - $15K2026-09-022026-09-25
Kevin HernHouseOK01▼ Sell$1K - $15K2026-08-312026-09-25
Kevin HernHouseOK01▼ Sell$1K - $15K2026-08-272026-09-25
Kevin HernHouseOK01▼ Sell$1K - $15K2026-08-192026-09-01
Rick LarsenHouseWA02▼ Sell$1K - $15K2025-10-062025-10-16
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-09-252025-10-07
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-09-232026-08-05
Julie JohnsonHouseTX32▲ Buy$1K - $15K2025-09-232026-08-05
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-09-112025-10-22
Tim MooreHouseNC14▼ Sell$1K - $15K2025-09-102025-10-10
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-08-132025-09-12
Shelley Moore CapitoSenateWV▼ Sell$1K - $15K2025-07-312025-08-04
Ritchie John TorresHouseNY15▼ Sell$1K - $15K2025-07-112025-08-20
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-06-242025-08-13
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-172025-08-13
Tommy TubervilleSenateAL▼ Sell$1K - $15K2021-03-292021-07-23
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2018-04-242019-05-09
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2018-04-052019-05-09